Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug

Published on 23/04/2025 at 09:11 - Modified on 23/04/2025 at 09:24

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals sees H1 net profit up 100.7-114.1% Y/Y	07-09	RE
Gan & Lee Pharmaceuticals' Insulin Aspart Receives Approval in Argentina	07-08	CI
Gan & Lee Pharmaceuticals Presents Multiple Results in Novel Diabetes Therapies At the American Diabetes Association's 85Th Scientific Sessions	06-21	CI
Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial	05-19	MT
Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10%	04-25	MT
Gan & Lee Pharmaceuticals' Q1 Profit Surged 225%, Operating Income Jumps 76%; Shares Jump 10%	04-25	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-24	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial Diabetes Drug	04-23	MT
Gan & Lee Pharma's Insulin Glargine Injection Gets Registration Nod in Pakistan	04-02	MT
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	04-01	CI
Gan & Lee Pharmaceuticals Doses First Subject for Phase II Clinical Trial of Bovanglutide Injection	03-11	MT
Gan & Lee Pharmaceuticals Announces First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide Injection for Overweight or Obesity	03-10	CI
Gan & Lee Pharma Doses First Subject for Insulin Drug's Phase III Trial; Shares Up 3%	02-18	MT
Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug	02-11	MT
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	01-02	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	12-16	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from SSE 180 Index	12-16	CI
Gan & Lee Pharmaceuticals Gets US FDA Approval for Clinical Trials of Weight Control Drug	12-13	MT
Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks	11-12	CI
Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults	11-11	CI
Gan & Lee Pharmaceuticals Doses First Patient in Psoriasis Drug Trial	24/10/24	MT
Gan & Lee Pharmaceuticals Q3 Profit Up 57%; Shares Climb 3%	23/10/24	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2024	22/10/24	CI
Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.	09/10/24	CI
Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares.	05/09/24	CI